TrialCancer medicine2023

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.

Ruben A Mesa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.